Cell Biotech Co., Ltd. (KOSDAQ:049960)

Market Cap	96.91B +5.9%
Revenue (ttm)	53.13B +6.4%
Net Income	10.13B -33.1%
EPS	1,479.00 -33.1%
Shares Out	6.84M
PE Ratio	9.57
Forward PE	n/a
Dividend	450.00 (3.13%)
Ex-Dividend Date	Dec 29, 2025

Volume	11,375
Average Volume	15,170
Open	14,500
Previous Close	14,400
Day's Range	14,030 - 14,500
52-Week Range	11,350 - 15,950
Beta	0.36
RSI	50.21
Earnings Date	Apr 2, 2026

About Cell Biotech

Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 101
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049960

Financial Performance

In 2025, Cell Biotech's revenue was 53.13 billion, an increase of 6.44% compared to the previous year's 49.91 billion. Earnings were 10.13 billion, a decrease of -33.06%.